<div class="OutlineElement Ltr SCXW262516729 BCX0"> <p class="Paragraph SCXW262516729 BCX0" lang="EN-US" paraid="370891868" paraeid="{60c94233-1549-4357-905a-ce1fbc1746e7}{238}"><span data-contrast="auto" xml:lang="EN-US" lang="EN-US" class="TextRun SCXW262516729 BCX0"><span class="NormalTextRun SCXW262516729 BCX0">Pa</span><span class="NormalTextRun SCXW262516729 BCX0">cli</span><span class="NormalTextRun SCXW262516729 BCX0">t</span><span class="NormalTextRun SCXW262516729 BCX0">axel-coated devices increase the risk of early major amputation in patients with chronic limb-threatening ischemia (CLTI) and tissue loss compared with</span><span class="NormalTextRun SCXW262516729 BCX0"> uncoated endovascular devices</span><span class="NormalTextRun ContextualSpellingAndGrammarErrorV2Themed SCXW262516729 BCX0">, a</span><span class="NormalTextRun SCXW262516729 BCX0"> </span><span class="NormalTextRun SCXW262516729 BCX0">sub</span><span class="NormalTextRun SCXW262516729 BCX0">study</span><span class="NormalTextRun SCXW262516729 BCX0"> of the SWEDEPAD-1 trial shows.</span></span><span class="EOP Selected SCXW262516729 BCX0" data-ccp-props="{}"> </span></p> </div> <div class="OutlineElement Ltr SCXW262516729 BCX0"> <p class="Paragraph SCXW262516729 BCX0" lang="EN-US" paraid="1322514292" paraeid="{1da87c45-0639-4ae4-bc73-9170b7daf201}{194}"><span data-contrast="auto" xml:lang="EN-US" lang="EN-US" class="TextRun SCXW262516729 BCX0"><span class="NormalTextRun SCXW262516729 BCX0">Fredrik Sellgren, MD, of the University of Gothenburg, Sweden, </span><span class="NormalTextRun SCXW262516729 BCX0">and </span><span class="NormalTextRun SpellingErrorV2Themed SCXW262516729 BCX0">colleages</span><span class="NormalTextRun SCXW262516729 BCX0">, reported these data in a manuscript published online this week in </span></span><span class="NormalTextRun SCXW262516729 BCX0"><em>Circulation: Cardiovascular Interventions</em>.</span><span class="EOP Selected SCXW262516729 BCX0" data-ccp-props="{}"> </span></p> </div> <div class="OutlineElement Ltr SCXW262516729 BCX0"> <p class="Paragraph SCXW262516729 BCX0" lang="EN-US" paraid="578891026" paraeid="{1c3a7754-62d9-48fc-a01b-3a007b6e479d}{41}"><span data-contrast="auto" xml:lang="EN-US" lang="EN-US" class="TextRun SCXW262516729 BCX0"><span class="NormalTextRun SCXW262516729 BCX0">CLTI plus tissue loss puts patients</span><span class="NormalTextRun SCXW262516729 BCX0"> with peripheral artery disease (PAD)</span><span class="NormalTextRun SCXW262516729 BCX0"> at </span><span class="NormalTextRun SCXW262516729 BCX0">high risk</span><span class="NormalTextRun SCXW262516729 BCX0"> for major amputations. </span><span class="NormalTextRun SCXW262516729 BCX0">Drug-coated devices are used most often in coronary interventions. </span><span class="NormalTextRun SCXW262516729 BCX0">Little is known about the impact of drug-coated devices </span><span class="NormalTextRun ContextualSpellingAndGrammarErrorV2Themed SCXW262516729 BCX0">in</span><span class="NormalTextRun SCXW262516729 BCX0"> </span><span class="NormalTextRun SCXW262516729 BCX0">CLTI.</span></span><span class="EOP Selected SCXW262516729 BCX0" data-ccp-props="{}"> </span></p> </div> <div class="OutlineElement Ltr SCXW262516729 BCX0"> <p class="Paragraph SCXW262516729 BCX0" lang="EN-US" paraid="1900064369" paraeid="{fab67ef1-e1a8-4393-9f0e-ad63c5df8ca1}{206}"><span data-contrast="auto" xml:lang="EN-US" lang="EN-US" class="TextRun SCXW262516729 BCX0"><span class="NormalTextRun SCXW262516729 BCX0">SWEDEPAD-1 (Swedish Drug-Elution Trial in Peripheral Artery Disease) was a pragmatic, multicenter, randomized, registry-based study</span><span class="NormalTextRun SCXW262516729 BCX0"> examining the use of drug-coated devices in PAD. Participants were randomized to receive revascularization with versus without </span><span class="NormalTextRun ContextualSpellingAndGrammarErrorV2Themed SCXW262516729 BCX0">a drug</span><span class="NormalTextRun SCXW262516729 BCX0">-coated technology.</span></span><span class="EOP Selected SCXW262516729 BCX0" data-ccp-props="{}"> </span></p> </div> <div class="OutlineElement Ltr SCXW262516729 BCX0"> <p class="Paragraph SCXW262516729 BCX0" lang="EN-US" paraid="1308256670" paraeid="{3237bbe0-48eb-45dd-8844-0b3f36033924}{233}"><span data-contrast="auto" xml:lang="EN-US" lang="EN-US" class="TextRun SCXW262516729 BCX0"><span class="NormalTextRun SCXW262516729 BCX0">The primary outcome for SWEDEPAD-1 was the amputation rate during the 1-year follow-up period. The outcomes were also assessed at 3-</span><span class="NormalTextRun SCXW262516729 BCX0">months</span><span class="NormalTextRun SCXW262516729 BCX0"> and 5-years follow-up.</span></span><span class="EOP Selected SCXW262516729 BCX0" data-ccp-props="{}"> </span></p> </div> <div class="OutlineElement Ltr SCXW262516729 BCX0"> <p class="Paragraph SCXW262516729 BCX0" lang="EN-US" paraid="1298737085" paraeid="{a0d40a5b-0ce6-4432-838f-2b93fe57e5d7}{103}"><span data-contrast="auto" xml:lang="EN-US" lang="EN-US" class="TextRun SCXW262516729 BCX0"><span class="NormalTextRun SCXW262516729 BCX0">A</span><span class="NormalTextRun SCXW262516729 BCX0"> total of 1,761 patients (median age=77 years, 60.1% male, 58.4% had diabetes) were included</span><span class="NormalTextRun SCXW262516729 BCX0"> in this </span><span class="NormalTextRun SpellingErrorV2Themed SCXW262516729 BCX0">sub</span><span class="NormalTextRun SpellingErrorV2Themed SCXW262516729 BCX0">analysis</span><span class="NormalTextRun SCXW262516729 BCX0">.</span><span class="NormalTextRun SCXW262516729 BCX0"> </span></span><span class="EOP Selected SCXW262516729 BCX0" data-ccp-props="{}"> </span></p> </div> <div class="OutlineElement Ltr SCXW262516729 BCX0"> <p class="Paragraph SCXW262516729 BCX0" lang="EN-US" paraid="569314615" paraeid="{9ca0fdb9-4869-45ab-b0ff-718979e15e67}{183}"><span data-contrast="auto" xml:lang="EN-US" lang="EN-US" class="TextRun SCXW262516729 BCX0"><span class="NormalTextRun SCXW262516729 BCX0">Patients who received the pa</span><span class="NormalTextRun SCXW262516729 BCX0">cli</span><span class="NormalTextRun SCXW262516729 BCX0">t</span><span class="NormalTextRun SCXW262516729 BCX0">axel-coated device had significantly higher rates of ipsilateral major amputation at 3-months post-procedure (10.4%) compared with patients who received an uncoated device (7.5%)</span><span class="NormalTextRun SCXW262516729 BCX0">.</span></span><span class="EOP Selected SCXW262516729 BCX0" data-ccp-props="{}"> </span></p> </div> <div class="OutlineElement Ltr SCXW262516729 BCX0"> <p class="Paragraph SCXW262516729 BCX0" lang="EN-US" paraid="710864667" paraeid="{5c19e3e0-02a4-42d1-9f7f-c12d94c3072f}{110}"><span data-contrast="auto" xml:lang="EN-US" lang="EN-US" class="TextRun SCXW262516729 BCX0"><span class="NormalTextRun SCXW262516729 BCX0">At 1-year follow-up, both groups had similar amputation rates (16.3% in coated </span><span class="NormalTextRun SCXW262516729 BCX0">group</span><span class="NormalTextRun SCXW262516729 BCX0"> and 14.6% in uncoated </span><span class="NormalTextRun SCXW262516729 BCX0">group</span><span class="NormalTextRun SCXW262516729 BCX0">), and these rates </span><span class="NormalTextRun SCXW262516729 BCX0">were similar</span><span class="NormalTextRun SCXW262516729 BCX0"> through 5-year follow-up. </span></span><span class="EOP Selected SCXW262516729 BCX0" data-ccp-props="{}"> </span></p> </div> <div class="OutlineElement Ltr SCXW262516729 BCX0"> <p class="Paragraph SCXW262516729 BCX0" lang="EN-US" paraid="1220955329" paraeid="{b4a867b1-86eb-4788-8f9d-d40b318f851b}{222}"><span data-contrast="auto" xml:lang="EN-US" lang="EN-US" class="TextRun SCXW262516729 BCX0"><span class="NormalTextRun SCXW262516729 BCX0">Patients in the coated device group had lower rates of target vessel reintervention at 1-year follow-up (13.6%) versus the uncoated device patients (18.0%), but this difference </span><span class="NormalTextRun SCXW262516729 BCX0">wasn’t</span><span class="NormalTextRun SCXW262516729 BCX0"> significant when</span><span class="NormalTextRun SCXW262516729 BCX0"> limb loss was included in the composite endpoint, the investigators emphasized.</span></span><span class="EOP Selected SCXW262516729 BCX0" data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></p> </div> <div class="OutlineElement Ltr SCXW262516729 BCX0"> <p class="Paragraph SCXW262516729 BCX0" lang="EN-US" paraid="1830789129" paraeid="{42deef07-4b32-4674-9f74-14aab0833103}{198}"><span data-contrast="auto" xml:lang="EN-US" lang="EN-US" class="TextRun SCXW262516729 BCX0"><span class="NormalTextRun SCXW262516729 BCX0">Overall, patients who received drug-coated devices for CLTI treatment in the SWEDEPAD-1 trial were at elevated risk for early amputation, despite having lower risk for </span><span class="NormalTextRun SCXW262516729 BCX0">reinterven</span><span class="NormalTextRun SCXW262516729 BCX0">tion, compared with patients who received uncoated devices.</span></span><span class="EOP Selected SCXW262516729 BCX0" data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></p> </div> <div class="OutlineElement Ltr SCXW262516729 BCX0"> <p class="Paragraph SCXW262516729 BCX0" lang="EN-US" paraid="813845522" paraeid="{bc617aee-18a6-4ceb-8ce9-6a367267da51}{38}"><span data-contrast="auto" xml:lang="EN-US" lang="EN-US" class="TextRun SCXW262516729 BCX0"><span class="NormalTextRun SCXW262516729 BCX0">Additionally, the benefit of the pa</span><span class="NormalTextRun SCXW262516729 BCX0">cli</span><span class="NormalTextRun SCXW262516729 BCX0">t</span><span class="NormalTextRun SCXW262516729 BCX0">axel-coated device was no longer useful when a composite endpoint including limb loss was evaluated, the investigators warned.</span></span><span class="EOP Selected SCXW262516729 BCX0" data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></p> </div> <div class="OutlineElement Ltr SCXW262516729 BCX0"> <p class="Paragraph SCXW262516729 BCX0" lang="EN-US" paraid="1132596986" paraeid="{8ac10edd-4dc8-40ea-9e25-80ad421d8dc6}{43}"><strong><span class="NormalTextRun SCXW262516729 BCX0">Source:</span><span class="EOP Selected SCXW262516729 BCX0" data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></strong></p> </div> <div class="OutlineElement Ltr SCXW262516729 BCX0"> <p class="Paragraph SCXW262516729 BCX0" lang="EN-US" paraid="1913221182" paraeid="{8ac10edd-4dc8-40ea-9e25-80ad421d8dc6}{83}"><span data-contrast="auto" xml:lang="EN-US" lang="EN-US" class="TextRun SCXW262516729 BCX0"><span class="NormalTextRun SCXW262516729 BCX0">Sellgren F, Falkenberg M, Andersson M, et al. Pa</span><span class="NormalTextRun SCXW262516729 BCX0">cli</span><span class="NormalTextRun SCXW262516729 BCX0">t</span><span class="NormalTextRun SCXW262516729 BCX0">axel-coated devices in patients with chronic limb-threatening ischemia and tissue loss undergoing </span><span class="NormalTextRun SpellingErrorV2Themed SCXW262516729 BCX0">infrainguinal</span><span class="NormalTextRun SCXW262516729 BCX0"> endovascular revascularization: Insights from the SWEDEPAD-1 trial. </span></span><em><span data-contrast="auto" xml:lang="EN-US" lang="EN-US" class="TextRun SCXW262516729 BCX0"><span class="NormalTextRun SCXW262516729 BCX0">Circ</span><span class="NormalTextRun SCXW262516729 BCX0"> Cardiovasc </span><span class="NormalTextRun SpellingErrorV2Themed SCXW262516729 BCX0">Interv</span></span></em><span class="NormalTextRun SCXW262516729 BCX0">. 2026 September 25 (Article in Press).</span><span class="EOP Selected SCXW262516729 BCX0" data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></p> </div> <div class="OutlineElement Ltr SCXW262516729 BCX0"> <p class="Paragraph SCXW262516729 BCX0" lang="EN-US" paraid="1047011120" paraeid="{650da06d-0b29-40e5-98e3-cc509b47f264}{247}"><strong><span data-contrast="auto" xml:lang="EN-US" lang="EN-US" class="TextRun MacChromeBold SCXW262516729 BCX0"><span class="NormalTextRun SCXW262516729 BCX0">Image Credit: </span><span class="NormalTextRun SCXW262516729 BCX0">Svetlana</span><span class="NormalTextRun SCXW262516729 BCX0"> – stock.adobe.com</span></span></strong><span class="EOP Selected SCXW262516729 BCX0" data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></p> </div>